Titles
- Antiviral drugs: Economic incentives and strategies for pandemic preparedness : report to congressional committees1
- Application of human factors engineering principles for combination products: questions and answers : guidance for industry and FDA staff1
- Artificial intelligence in health care: benefits and challenges of machine learning technologies for medical diagnostics : report to congressional requesters1
- Assessing the credibility of computational modeling and simulation in medical device submissions: guidance for industry and Food and Drug Administration staff1
- Assessing the effects of food on drugs in INDs and NDAs: clinical pharmacology considerations1
- Behavioral health: Available workforce information and federal actions to help recruit and retain providers : report to congressional requesters1
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- Best practices for convening a GRAS panel: guidance for industry1
- Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff1
- Bureau of Prisons: assessment of health care reentry policies and procedures needed : report to congressional committees1
- CARES Act: experts identified safeguards to help selected HHS agencies protect against potential political interference : report to congressional requesters1
- CDC has improved the nursing home reporting process for COVID-19 Data in NHSN, but challenges remain1
- CDC provided oversight and assistance: however, ELC recipients still faced challenges in implementing COVID-19 screening testing programs1
- CDC’S Vaccines for Children program recipients did not conduct site visits at some providers as required1
- CDC’s internal control weaknesses led to its initial COVID-19 test kit failure, but CDC ultimately created a working test kit1
- CDER’s program for the recognition of voluntary consensus standards related to pharmaceutical quality: guidance for industry1
- CMS can do more to leverage Medicare claims data to identify unreported incidents of potential abuse or neglect1
- CMS has opportunities to strengthen states’ oversight of Medicaid Managed Care Plans’ reporting of medical loss ratios1
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- CMS should take further action to address states with poor performance in conducting nursing home surveys1